Linling Zhou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Linling Zhou has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Liqiang Pan
Laboratory of Precision Medicine and Biopharmaceuticals, School of Pharmacy, Zhejiang University, Hangzhou, China; Department of Pharmacy, the Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang University, Hangzhou, China; Institute of Fundamental and Transdisciplinary Research, Zhejiang University, Hangzhou, China
2 shared publications Jiaqi Zhao
School of Pharmacy and Department of Pharmacy, The Second Affiliated Hospital, Zhejiang University, Hangzhou 310058, China
1 shared publication- Jiaqi Zhao
Department of Pharmacy, the Second Affiliated Hospital, School of Medicine and College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China
1 shared publication Jie Bi
School of Pharmacy and Department of Pharmacy, The Second Affiliated Hospital, Zhejiang University, Hangzhou 310058, China
1 shared publication- Jie Bi
Department of Pharmacy, the Second Affiliated Hospital, School of Medicine and College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China
1 shared publication Jisheng Wang
The Third Hospital of Mianyang (Sichuan Mental Health center), Mianyang 612000, China
1 shared publication
Latest Publications
- Open Access
- 7 February 2026
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 16 (9) , 5540-5552
APRIL-driven BCMA/TACI dual-targeted ligand–drug conjugates for selective and potent therapy of multiple myeloma
- 7 February 2026
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 16 (9) , 5540-5552
Open AccessAPRIL-driven BCMA/TACI dual-targeted ligand–drug conjugates for selective and potent therapy of multiple myeloma
- Open Access
- 13 March 2025
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 13 (3) , e010140
Leveraging T cell co-stimulation for enhanced therapeutic efficacy of trispecific antibodies targeting prostate cancer
Background: Clinical trials have demonstrated the efficacy of bispecific antibodies in eliciting potent antitumor responses by redirecting T cells to target cancer cells, particularly for the treatment of hematologic malignancies. However, their efficacy against solid tumors is limited by intratumoral T-cell dysfunction and inadequate persistence. The co-stimulatory domains of 4-1BB, OX40, and CD28 are most widely used in engineering chimeric antigen receptor T-cells to augment T-cell responses. Methods: In this study, we designed three co-stimulatory trispecific T cell-engaging antibodies (TriTCEs) that target Prostate-specific membrane antigen, CD3, and an additional co-stimulatory receptor(OX40, 4-1BB, or CD28). We conducted comparative profiling of the attributes of distinct co-stimulatory signals to T-cell functions in prostate cancer models. Results: Co-stimulatory trispecific T-cell engagers enhance T-cell activation, proliferation, and display tumor cell-killing activity in vitro. These trispecific antibodies further boosted antitumor activity in humanized mouse xenograft models and increased the infiltration of CD45+ immune cells into solid tumors. Specifically, TriTCE-4-1BB and TriTCE-CD28 selectively promoted the expansion of effector memory T cells and increased the presence of CD4+ T cells more than TriTCE-OX40. T cells stimulated with TriTCE-4-1BB exhibited reduced exhaustion. Furthermore, T cells treated with co-stimulatory trispecific antibodies demonstrated enhanced metabolic activity characterized by increased oxidative phosphorylation and elevated glycolysis. Conclusions: Collectively, incorporating co-stimulatory receptor targeting domains represents a potentially effective strategy to unlock the full therapeutic potential of T-cell-engaging antibodies for the treatment of solid tumors.
- 13 March 2025
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 13 (3) , e010140
Open AccessLeveraging T cell co-stimulation for enhanced therapeutic efficacy of trispecific antibodies targeting prostate cancer
Background: Clinical trials have demonstrated the efficacy of bispecific antibodies in eliciting potent antitumor responses by redirecting T cells to target cancer cells, particularly for the treatment of hematologic malignancies. However, their efficacy against solid tumors is limited by intratumoral T-cell dysfunction and inadequate persistence. The co-stimulatory domains of 4-1BB, OX40, and CD28 are most widely used in engineering chimeric antigen receptor T-cells to augment T-cell responses. Methods: In this study, we designed three co-stimulatory trispecific T cell-engaging antibodies (TriTCEs) that target Prostate-specific membrane antigen, CD3, and an additional co-stimulatory receptor(OX40, 4-1BB, or CD28). We conducted comparative profiling of the attributes of distinct co-stimulatory signals to T-cell functions in prostate cancer models. Results: Co-stimulatory trispecific T-cell engagers enhance T-cell activation, proliferation, and display tumor cell-killing activity in vitro. These trispecific antibodies further boosted antitumor activity in humanized mouse xenograft models and increased the infiltration of CD45+ immune cells into solid tumors. Specifically, TriTCE-4-1BB and TriTCE-CD28 selectively promoted the expansion of effector memory T cells and increased the presence of CD4+ T cells more than TriTCE-OX40. T cells stimulated with TriTCE-4-1BB exhibited reduced exhaustion. Furthermore, T cells treated with co-stimulatory trispecific antibodies demonstrated enhanced metabolic activity characterized by increased oxidative phosphorylation and elevated glycolysis. Conclusions: Collectively, incorporating co-stimulatory receptor targeting domains represents a potentially effective strategy to unlock the full therapeutic potential of T-cell-engaging antibodies for the treatment of solid tumors.